Irritable Bowel Syndrome News

A phase 2b trial of two oral colonic release formulations of Linzess for constipation-predominant irritable bowel syndrome has been initiated, the manufacturer announced.

Zonulin serum levels were found to be increased in patients with nonceliac gluten sensitivity and irritable bowel syndrome comparable to those with celiac disease, according to data presented at UEG Week 2015.

Allergan and Ironwood announced that Allergan has acquired rights to Constella in the European Union, Switzerland, Turkey and the Commonwealth of Independent States, and has reacquired rights to Linzess in Mexico from Almirall.

Commonwealth Laboratories has announced a national agreement with Quest Diagnostics that will expand the availability of IBSchek, its new blood test for irritable bowel syndrome.

The second phase 2 clinical trial of SYN-010 for the treatment of constipation-predominant irritable bowel syndrome has been initiated, the manufacturer announced.

Mayo Clinic researchers have performed a systematic review and meta-analysis which identified three new tests that can serve as biomarkers for idiopathic bile acid diarrhea in patients with diarrhea-predominant functional bowel disorders.

Microbial composition and diversity in unprepared sigmoid colon mucosa differed insignificantly between patients with irritable bowel syndrome and healthy controls compared to the differences in the fecal microbiota between both groups, according to recent study data.

A recent study found nearly a quarter of patients who meet Rome III criteria for diarrhea-predominant irritable bowel syndrome have idiopathic bile acid diarrhea.

In recent weeks, numerous developments in irritable bowel syndrome have been reported by gastroenterology professional societies and in the journals, including new systematic reviews and a randomized trial of dietary interventions, and more recently, a wealth of new data on IBS treatments and comorbidities presented at the AGA’s 2015 James W. Freston Conference in Chicago.

Patients with irritable bowel syndrome had significantly higher perceived stress compared with healthy controls, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago.